Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

NCT01314261 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C
Hepatitis C Virus (HCV) Infection

Interventions

DRUG: ABT-267
DRUG: Pegylated interferon (pegIFN)
DRUG: Ribavirin (RBV)
OTHER: Placebo for ABT-267

Sponsor

AbbVie (prior sponsor, Abbott)